Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 6/20 | 0.40 |
| ▸ | MTNR1A | P48039 | 4/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.33 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.33 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17669566 | 0.82 | CYP2A6 (0.41) | CYP2A6MTNR1ACA2KEAP1NFE2L2 | |
| SCHEMBL17669439 | 0.81 | CYP2A6 (0.41) | CYP2A6MTNR1ACA2KEAP1NFE2L2 | |
| SCHEMBL17669474 | 0.81 | FFAR1 (0.45) | CYP2A6 | |
| SCHEMBL3682441 | 0.74 | CYP2A6 (0.62) | CYP2A6CA2KEAP1NFE2L2 | |
| SCHEMBL3164828 | 0.73 | CYP2A6 (0.66) | CYP2A6CA2 | |
| SCHEMBL23987208 | 0.71 | ALDH1A1 (0.47) | MTNR1A | |
| SCHEMBL16727006 | 0.71 | CYP2A6 (0.39) | CYP2A6MTNR1ACA2 | |
| SCHEMBL17669426 | 0.71 | FFAR1 (0.54) | CYP2A6 | |
| SCHEMBL17669469 | 0.71 | FFAR1 (0.46) | CYP2A6 | |
| SCHEMBL17669472 | 0.69 | CYP2A6 (0.43) | CYP2A6CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10662170-B2 | Substituted benzothiophenyl derivatives as GPR40 agonists for the treatment of type II diabetes | JANSSEN PHARMACEUTICA NV (BE) | 2020-05-26 | — | — | US | disclosed |
| US-10195178-B2 | GPR40 agonists in anti-diabetic drug combinations | JANSSEN PHARMACEUTICA NV (BE) | 2019-02-05 | — | — | US | disclosed |
| US-10131648-B2 | Substituted benzothiophenyl derivatives as GPR40 agonists for the treatment of type II diabetes | JANSSEN PHARMACEUTICA NV (BE) | 2018-11-20 | — | — | US | disclosed |
| US-10106553-B2 | Substituted benzothiophenyl derivatives as GPR40 agonists for the treatment of type II diabetes | JANSSEN PHARMACEUTICA NV (BE) | 2018-10-23 | — | — | US | disclosed |
| US-20170362196-A1 | SUBSTITUTED BENZOTHIOPHENYL DERIVATIVES AS GPR40 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES | JANSSEN PHARMACEUTICA NV (BE) | 2017-12-21 | — | — | US | disclosed |
| WO-2017180457-A1 | GPR40 AGONISTS IN ANTI-DIABETIC DRUG COMBINATIONS | JANSSEN PHARMACEUTICA NV (BE) | 2017-10-19 | — | — | WO | disclosed |
| WO-2017180571-A1 | SUBSTITUTED BENZOTHIOPHENYL DERIVATIVES AS GPR40 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES | JANSSEN PHARMACEUTICA NV (BE) | 2017-10-19 | — | — | WO | disclosed |
| US-9790198-B2 | Substituted benzothiophenyl derivatives as GPR40 agonists for the treatment of type II diabetes | JANSSEN PHARMACEUTICA NV (BE) | 2017-10-17 | — | — | US | disclosed |
| US-20170290800-A1 | GPR40 AGONISTS IN ANTI-DIABETIC DRUG COMBINATIONS | JANSSEN PHARMACEUTICA NV (BE) | 2017-10-12 | — | — | US | disclosed |
| US-20170291908-A1 | SUBSTITUTED BENZOTHIOPHENYL DERIVATIVES AS GPR40 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES | JANSSEN PHARMACEUTICA NV (BE) | 2017-10-12 | — | — | US | disclosed |
| EP-3204361-A1 | SUBSTITUTED BENZOTHIOPHENYL DERIVATIVES AS GPR40 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES | Janssen Pharmaceutica N.V. (BE) | 2017-08-16 | — | — | EP | disclosed |
| CN-107001281-A | Substituted benzothiophene radical derivative is used as the GPR40 activators for treating type ii diabetes | 詹森药业有限公司 | 2017-08-01 | — | — | CN | disclosed |
| WO-2016057731-A1 | SUBSTITUTED BENZOTHIOPHENYL DERIVATIVES AS GPR40 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES | JANSSEN PHARMACEUTICA NV (BE) | 2016-04-14 | — | — | WO | disclosed |
| US-20160102071-A1 | SUBSTITUTED BENZOTHIOPHENYL DERIVATIVES AS GPR40 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES | JANSSEN PHARMACEUTICA NV (BE) | 2016-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170290800-A1 | GPR40 AGONISTS IN ANTI-DIABETIC DRUG COMBINATIONS | GPR119, GLP1R, GPR65 | CYP2A6 1416/4885MTNR1A 218/4885CA2 2034/4885 |
| US-20170291908-A1 | SUBSTITUTED BENZOTHIOPHENYL DERIVATIVES AS GPR40 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES | GPR119, GPR65, GPR52 | CYP2A6 1893/4885MTNR1A 97/4885CA2 3642/4885 |
| US-10195178-B2 | GPR40 agonists in anti-diabetic drug combinations | GPR119, GLP1R, GPR65 | CYP2A6 1416/4885MTNR1A 218/4885CA2 2034/4885 |
| US-20170362196-A1 | SUBSTITUTED BENZOTHIOPHENYL DERIVATIVES AS GPR40 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES | GPR119, GPR52, GPR65 | CYP2A6 1320/4885MTNR1A 95/4885CA2 3426/4885 |
| US-10662170-B2 | Substituted benzothiophenyl derivatives as GPR40 agonists for the treatment of type II diabetes | GPR119, GPR52, GPR65 | CYP2A6 1320/4885MTNR1A 95/4885CA2 3426/4885 |
| US-10106553-B2 | Substituted benzothiophenyl derivatives as GPR40 agonists for the treatment of type II diabetes | GPR119, GPR65, GPR52 | CYP2A6 1893/4885MTNR1A 97/4885CA2 3642/4885 |
| US-10131648-B2 | Substituted benzothiophenyl derivatives as GPR40 agonists for the treatment of type II diabetes | GPR119, GPR52, GPR65 | CYP2A6 1320/4885MTNR1A 95/4885CA2 3426/4885 |
| US-20160102071-A1 | SUBSTITUTED BENZOTHIOPHENYL DERIVATIVES AS GPR40 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES | GPR119, GPR52, GPR65 | CYP2A6 1320/4885MTNR1A 95/4885CA2 3426/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.